摘要
卵巢癌为妇科常见恶性肿瘤之一，其病死率居妇科恶性肿瘤病死率之首。75％的卵巢癌发现时已为晚期，5年存活率为15％～30％。卵巢癌患者虽经减灭术及化疗，但仍有85％的患者会出现复发，因此对复发性卵巢癌（Recurrent ovarian cancer）的及时治疗非常重要。
出处
《中国医药导报》
CAS
2007年第12X期5-7,共3页
China Medical Herald
参考文献9
-
1Chou HH,Wang KL,Chen CA,et al.Pegylated liposomal doxorubicin(Lipo-Dox)for Platinum-resistant or refractory epithelial ovarian carcinoma:a Taiwan Residents gynecologic oncology group study with long term follow-up[].Gynecologic Oncology.2006
-
2Petru E,Angleitner-Boubenizek L,Reinthaller A,et al.Combined PEG li-posomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum refractory and resistant ovarian cancerafter previous platinum-taxane therapy:A phaseⅡAusrtian AGO study[].Gynecologic Oncology.2006
-
3Delaloge S,Laadem A,Taamma A.Pilot study of the paclitaxel,oxaliplatin,and cisplatin combination in patients with advanced/recurrent ovarian cancer[].American Journal of Clinical Oncology.2000
-
4Markman M,Blessing J,Rubin SC,et al.PhaseⅡtrial of weekly paclitax-el(80mg/m2)in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:a Gynecologic Oncolohy Group study[].Gynecologic Oncology.2006
-
5Tait DL,Obermiller PS,Hatmaker AR,et al.Ovarian cancer BRCA1gene therapy:PhaseⅠandⅡtrial differences in immune response and vector stability[].Clinical Cancer Research.1999
-
6David Spriggs.Optimal sequencing in the treatment of recurrent ovarian cancer[].Gynecologic Oncology.2003
-
7Wen SF,Mahavni V,Quijano E,et al.Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer[].Cancer Gene Therapy.2003
-
8Hasenburg A,Fischer DC,Tong XW,et al.Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer[].International Journal of Gynecological Cancer.2002
-
9Bciman ML.Future directions in the surgical management of ovarian cancer[].Gynecologic Oncology.2003
同被引文献21
-
1蒋凤荣,张旭,范俊,康赟.麦冬药理作用研究进展[J].中医药学刊,2006,24(2):236-237. 被引量：102
-
2谭开基,曹洋,陈锐深.卵巢癌的中医治疗体会[J].中医药学刊,2006,24(3):505-506. 被引量：9
-
3李雅静,石红.P53、HSP70在卵巢癌中的研究进展[J].基层医学论坛,2006,10(10):935-937. 被引量：4
-
4刘庆伟.《PET/CT肿瘤学》出版发行[J].中华核医学杂志,2006,26(4):221-221. 被引量：1
-
5黄守松,陈丽贤,傅文红,杜佩妍.晚期卵巢癌治疗方法对预后的影响[J].中国医药导报,2007,4(01Z):32-33. 被引量：5
-
6Sundstrom s,Bremnes RM,Kaasa S,et al.Second-line chemotherapy in recurrent small cell lung cancer:results from a crossover schedule after primary treatment mt h cisplatinand etoposide(EP-regimen)or cyclophosphamide,epirubicin and vlncristin(CEV-regimen)[J].Lung Cancer,2005,48(2):251-261.
-
7Pfisterer J,Plante M,Vergote I,et al.Gemcitabine/carbop latin(GC)vs carboplatinin(C)platinum sensitive recurrent ovariancancer(OVCA):results of a Gynecologic Cancer Intergroup randomized phase Ⅲ trial of the AGO OVAR,the NCIC CTG and the EORTC GCG[J].Proc Am Soc Clin Oncol,2004,449:5005.
-
8Seliger G,Mueller LP,Büchele T,et al.Salvage chemotheray with docetaxel,oxaliplatin and gemcitabine in platinum-pretreated advanced epithelial ovarian cancer:P reliminary results of a phase Ⅱ study(Abstact)[J].Proc Am Soc Clin Oncol,2002,21:864.
-
9贺彬彬,孙淑华.复发性卵巢癌的治疗现状和进展[J].实用医学杂志,2010,26(8):1280-1281. 被引量：14
-
10郝颂华,杨玲竹,王欣.参麦注射液联合TP方案治疗晚期卵巢癌疗效观察[J].肿瘤基础与临床,2010,23(4):315-316. 被引量：8
引证文献3
-
1蔡永杰,吕洪锦.^18F-FDGPET-CT的SUV值在预测卵巢癌患者术后化疗的反应性的应用[J].中国当代医药,2008,15(24):31-32. 被引量：2
-
2王海存.吉西他滨联合奥沙利铂治疗晚期复发上皮性卵巢癌的临床研究[J].中国当代医药,2010,17(22):96-97. 被引量：4
-
3屈小会,马萌,姬芳琴,康汝光,车虹彩.紫杉醇与卡铂联合参麦注射液对中晚期卵巢癌患者外周血T细胞亚群及血清MMP-9、VEGF水平的影响[J].现代中西医结合杂志,2019,28(20):2237-2240. 被引量：12
二级引证文献18
-
1杨爽,沈影,韩凤娟.中医药对卵巢癌的治疗作用及研究进展[J].辽宁中医杂志,2021,48(10):202-207. 被引量：17
-
2陆勤美,许燕.紫杉醇联合吉西他滨治疗复发性卵巢癌患者的护理[J].解放军护理杂志,2011,28(20):52-54. 被引量：4
-
3祝传宝,周世辉.奥沙利铂联合用药治疗卵巢癌的研究进展[J].中国医药指南,2012,10(9):61-63. 被引量：4
-
4孙罡.吉西他滨联合奥沙利铂治疗晚期复发性卵巢癌的临床疗效[J].中国医药指南,2013,11(7):239-240. 被引量：4
-
5曹硕.吉西他滨联合奈达铂治疗铂类敏感复发上皮性卵巢癌的疗效观察[J].中国医学工程,2013,21(4):106-107. 被引量：1
-
6单前进,胡玉川.非小细胞肺癌PET-CT显像标准化摄取值与相关肿瘤标记物的相关性[J].中国当代医药,2013,20(14):128-129. 被引量：1
-
7于丽娟,徐继有,李迎辞,楚春雨.^18F-FDG PET/CT在卵巢癌复发和转移上的临床价值[J].实用肿瘤学杂志,2013,27(3):211-214. 被引量：5
-
8周樊臣.卡铂与紫杉醇脂质体联合治疗卵巢癌的效果分析[J].医药前沿,2021,11(4):41-42.
-
9罗蕙雨,张翠娟,林金凤.多西他赛联合卡铂治疗对卵巢癌患者机体免疫状态及血流参数的影响[J].中国当代医药,2021,28(11):17-20. 被引量：3
-
10周樊臣.紫杉醇联合卡铂治疗晚期卵巢癌患者的效果观察[J].医药前沿,2021,11(6):125-126.
-
1Kaijian Lei Yuming Jia Biao Wei Yongxiang Xiong Jing Wang.ATP生物荧光肿瘤药敏在复发卵巢癌并腹水化疗中的应用价值(英文)[J].The Chinese-German Journal of Clinical Oncology,2008,7(9):542-545. 被引量：1
-
2Yuan Wang,Jin-Jin Yu,Ting Zhu,Ling Xu,Ming Xu,Yu-Zheng Huang,Hong Pu,Chun-Qing Yu.Analysis of diferentially expressed protein from primary and recurrent ovarian cancer serum[J].Asian Pacific Journal of Tropical Medicine,2012,5(7):573-576. 被引量：5
